A collaborative framework for uncovering molecular and cellular drivers of VCID: Foundations for future interventions

M Luisa Iruela-Arispe1, Jason D Hinman2, Andrew C Yang3,4,5,6

  • 1Northwestern CWOW. Northwestern University, Chicago, Illinois, USA.

Insights

Vascular factors significantly contribute to dementia, including Alzheimer's disease. The Vascular Contributions to Cognitive Impairment and Dementia (VCID) network aims to develop new therapies targeting these vascular deficits.

Area of Science:

  • Neuroscience
  • Gerontology
  • Vascular Biology

Background:

  • Vascular factors are increasingly recognized as major contributors to dementia, including Alzheimer's disease.
  • The precise mechanisms linking vascular deficits to cognitive decline and dementia remain incompletely understood.
  • Therapeutic strategies targeting vascular contributions to dementia are limited.

Purpose of the Study:

  • To address the unmet need for effective treatments for dementia stemming from vascular deficits.
  • To foster collaboration and advance research through the establishment of the VCID Center Without Walls (CWOW) network.
  • To identify and explore research gaps and opportunities in vascular contributions to cognitive impairment and dementia.

Main Methods:

  • Establishment of a collaborative network (VCID CWOW) involving multiple research institutes.
  • Focus on understanding the mechanisms by which vascular deficits impact cognitive function.
  • Development and testing of novel therapeutic approaches targeting vascular pathways in dementia.

Main Results:

  • The VCID CWOW network has been established to unite researchers across the US.
  • The network aims to accelerate the understanding of vascular contributions to cognitive impairment and dementia.
  • Focus on identifying and addressing critical knowledge gaps in the field.

Conclusions:

  • Vascular deficits are a critical factor in dementia pathogenesis, necessitating targeted therapeutic development.
  • The VCID CWOW network represents a significant collaborative effort to advance dementia research.
  • Future research will focus on translating mechanistic insights into effective treatments for dementia.

Related Concept Videos

Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...